Latest News and Press Releases

First-in-Human Results Demonstrate Favorable Safety and Pharmacokinetics Profile AI Aided Target Engagement Research Advancing Development of Novel Biomarkers SOLANA BEACH, Calif., June 29, 2026 ...

Alaunos Reports New Preclinical ALN1003 Data Showing Lower Liver Weight After Adjustment for Body Fat Percentage in 48-Day DIO Mouse Study

Phoenix, Arizona, June 29, 2026 (GLOBE NEWSWIRE) -- As Americans prepare to celebrate the 250th anniversary of the United States, Aqua-Tots Swim School is encouraging families to add one more item...

MCLEAN, Va., June 29, 2026 (GLOBE NEWSWIRE) -- Cycurion, Inc. (NASDAQ: CYCU) (“Cycurion” or the “Company”), a leading provider of AI-driven cybersecurity, IT security solutions, and managed...

Clinically meaningful improvements in skin symptoms reported as early as week 4 and sustained over the 48-week study period Data presented at the 6th World Congress of Cutaneous Lymphomas meeting in...

LEXINGTON, Mass., June 29, 2026 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to leveraging genetics to treat neurological diseases, today...

Key member of management ranks at top 2% of researchers in the field of laboratory diagnostics and top 2.5% of all researchers worldwide, based on H-index of 58Recent studies advanced science of...

NAPLES, Fla., June 29, 2026 (GLOBE NEWSWIRE) -- via IBN – HealthLynked Corp. (OTCQB: HLYK), a leader in healthcare technology, patient engagement, and care coordination, today announced the launch...

EMERGE is a global, randomized, multicenter, placebo-controlled Phase 3 trial that will evaluate claseprubart 300mg/2mL S.C. dosed Q2W and Q4W vs. placebo, with top-line results anticipated in 2H’28  ...

Diranersen presentation will feature Phase 2 CELIA data in early Alzheimer’s disease, including clinical, biomarker and safety results for Biogen’s investigational tau-targeting ASO, following topline...